PRA Health Sciences (PRAH) Tops Q3 EPS by 29c, Revenues Beat; Raises FY20 EPS/Revenue Guidance Above Consensus

Go back to PRA Health Sciences (PRAH) Tops Q3 EPS by 29c, Revenues Beat; Raises FY20 EPS/Revenue Guidance Above Consensus

PRA Health Sciences (PRAH) PT Raised to $110 at Mizuho Securities

November 5, 2020 12:48 PM EST

Mizuho Securities analyst Ann Hynes raised the price target on PRA Health Sciences (NASDAQ: PRAH) to $110.00 (from $108.00) while maintaining a Neutral rating.

... More